Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hyseq -- Ignore unavailable to you. Want to Upgrade?

To: John Starks who wrote (6)	3/23/1999 10:08:00 PM
From: Ignite44	Read Replies (2) \| Respond to of 11

John, If you don't mind, I'd like to ask a question about the potential products being researched by companies like Hyseq and Affx. I've been a shareholder of IDBEF for several years waiting for them to develop dna tests using what they call 'cycling probe' technology. They've finally succeeded in creating a highly accurate and fast test targeting methicillin resistant staphylococcus aureus and filed for FDA approval on March 1. The product will consist of a kit that is used in hospitals to identify people with this bug and isolate them quickly. Their next diagnostic product will id vancomycin resistant enterococcus, another killer in hospitals. My question is will the chips being developed by Hyseq and Affx be able to do pretty much the same thing? If so, do you have an opinion on how soon they'll be available ? I thought IDBEF's tests had potential to sell but the market isn't reacting to their filing with the FDA and I'm wondering if it's because their technology is too little, too late in view of what's being developed elsewhere. Thanks in advance.